{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:50Z","timestamp":1790704370596,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000769","name":"University of Oxford","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The COVID-19 pandemic has presented unique challenges for the clinical trial community, both in the rapid establishment of COVID-19 clinical trials and many existing non-COVID-19 studies either being temporarily paused (whether that is a complete pause or pause in some activities) and\/or adapting their processes. Trial managers have played a key role in decision-making, undertaking risk assessments and adapting trial processes, working closely with other members of the research team. This article presents some of the ways in which trial management processes have been altered and the key role that trial managers have played. It has been born out of discussions between trial managers in the UK who are members of the UK Trial Managers\u2019 Network (UKTMN), a national network of trial management professionals managing non-commercial trials.<\/jats:p><jats:p>In these unprecedented times, clinical trials have faced many uncertainties and broad-ranging challenges encompassing a range of activities including prioritising patient safety amidst the pandemic, consenting and recruiting new participants into trials, data collection and management and intervention delivery. In many cases, recruitment has been paused whilst mitigations have been put in place to continue data collection. Innovative solutions have been implemented to ensure we continue, where possible, to deliver high-quality clinical trials. Technology has provided many solutions to these challenges, and trial managers have adapted to new ways of working whilst continuing to deliver their clinical trials. Trial management groups are now faced with new uncertainties around re-starting clinical trials, and it is unclear currently how this will go, though working together with sponsors, funders and site teams is clearly a priority.<\/jats:p><jats:p>Clinical trial teams have worked together to ensure their trials have adapted quickly whilst ensuring participant safety is given utmost importance. There are clear examples where the trial community have come together to share experiences and expertise, and this should continue in the future to ensure the innovative practices developed become embedded in the design and conduct of clinical trials in the future.<\/jats:p>","DOI":"10.1186\/s13063-020-04711-6","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T12:02:41Z","timestamp":1599825761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["It is unprecedented: trial management during the COVID-19 pandemic and beyond"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-4533","authenticated-orcid":false,"given":"Eleanor J.","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Breeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonaidh","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Constable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsteen","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry","family":"Meakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Mironov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Quann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"4711_CR1","unstructured":"The World Health Organisation. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19: 11 March 2020 2020 https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2D%2D-11-march-2020. [Accessed 4 Jun 2020]."},{"key":"4711_CR2","volume-title":"COVID-19 research","author":"Health Research Authority","year":"2020","unstructured":"Health Research Authority. COVID-19 research 2020. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/. [Accessed 4 Jun 2020]."},{"key":"4711_CR3","volume-title":"Urgent public health COVID-19 studies","author":"National Institute for Health Research","year":"2020","unstructured":"National Institute for Health Research. Urgent public health COVID-19 studies 2020 https:\/\/www.nihr.ac.uk\/covid-studies\/. [Accessed 4 Jun 2020]."},{"key":"4711_CR4","volume-title":"Q&A on the impact of COVID-19 on research funded or supported by NIHR","author":"National Institute for Health Research","year":"2020","unstructured":"National Institute for Health Research. Q&A on the impact of COVID-19 on research funded or supported by NIHR 2020 https:\/\/www.nihr.ac.uk\/documents\/qanda-on-the-impact-of-covid-19-on-research-funded-or-supported-by-nihr\/24467 [Accessed 4 Jun 2020]."},{"key":"4711_CR5","volume-title":"DHSC issues guidance on the impact of COVID-19 on research funded or supported by NIHR","author":"National Institute for Health Research","year":"2020","unstructured":"National Institute for Health Research. DHSC issues guidance on the impact of COVID-19 on research funded or supported by NIHR 2020. https:\/\/www.nihr.ac.uk\/news\/dhsc-issues-guidance-on-the-impact-on-covid-19-on-research-funded-or-supported-by-nihr\/24469 [Accessed 4 Jun 2020]."},{"key":"4711_CR6","volume-title":"Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency. Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic. 2020."},{"key":"4711_CR7","unstructured":"BioMed Central ISRCTN registry. ISRCTN63268739: female urgency, trial of Urodynamics as routine evaluation. http:\/\/www.isrctn.com\/ISRCTN63268739 [Accessed 15 Jun 2020]."},{"key":"4711_CR8","unstructured":"BioMed Central ISRCTN Registry. The forearm fracture recovery in children evaluation study. http:\/\/www.isrctn.com\/ISRCTN13955395. [Accessed 15 Jun 2020]."},{"key":"4711_CR9","unstructured":"National Institute of Health ClinicalTrials.gov. registry. NCT04204915: The early valve replacement in severe ASYmptomatic Aortic Stenosis Study (EASY-AS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04204915. [Accessed 16 Jun 2020]."},{"key":"4711_CR10","unstructured":"ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6 ICH Consensus Guideline 2016."},{"key":"4711_CR11","unstructured":"Health Research Authority. Informing participants and seeking consent 2019 [Available from: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/best-practice\/informing-participants-and-seeking-consent\/. [Accessed 4 Jun 2020]."},{"key":"4711_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-11-78","volume":"11","author":"B Farrell","year":"2010","unstructured":"Farrell B, Kenyon S, Shakur H. Managing clinical trials. Trials. 2010;11:1\u20136.","journal-title":"Trials."},{"key":"4711_CR13","unstructured":"UK Trial Managers\u2019 Network. A guide to efficient trial management version 6 [Accessed 4 Jun 2020]."},{"key":"4711_CR14","unstructured":"National Institute of Health ClinicalTrials.gov. NCT03615040: Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03615040 [Accessed 15 Jun 2020]."},{"key":"4711_CR15","unstructured":"BioMed Central ISRCTN Registry. ISRCTN89654042: Fluids exclusively enteral from day one in premature infants. http:\/\/www.isrctn.com\/ISRCTN89654042 [Accessed 15 June 2020]."},{"key":"4711_CR16","unstructured":"BioMed Central ISRCTN Registry. ISRCTN10497306: Bisoprolol in COPD study http:\/\/www.isrctn.com\/ISRCTN10497306. [Accessed 19 June 2020]."},{"key":"4711_CR17","unstructured":"BioMed Central ISRCTN Registry. ISRCTN15236311 The smoking cessation in pregnancy incentives trial. http:\/\/www.isrctn.com\/ISRCTN15236311 [Accessed 16 June 2020]."},{"issue":"1","key":"4711_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1186\/s13063-020-04388-x","volume":"21","author":"E Crowley","year":"2020","unstructured":"Crowley E, Treweek S, Banister K, Breeman S, Constable L, Cotton S, et al. Using systematic data categorisation to quantify the types of data collected in clinical trials: the DataCat project. Trials. 2020;21(1):535.","journal-title":"Trials."},{"key":"4711_CR19","volume-title":"Restart framework","author":"National Institute for Health Research","year":"2020","unstructured":"National Institute for Health Research. Restart framework. 2020 https:\/\/www.nihr.ac.uk\/documents\/restart-framework\/24886. [Accessed 4 Jun 2020]."},{"key":"4711_CR20","unstructured":"BioMed Central ISRCTN registry. ISRCTN16912075: RECOVERY respiratory support: respiratory strategies in patients with coronavirus COVID-19 - CPAP, high-flow nasal oxygen and standard care: http:\/\/www.isrctn.com\/ISRCTN16912075 [Accessed 15 Jun 2020]."},{"issue":"1","key":"4711_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13063-015-0908-6","volume":"16","author":"D Townsend","year":"2015","unstructured":"Townsend D, Mills N, Savovi\u0107 J, Donovan JL. A systematic review of training programmes for recruiters to randomised controlled trials. Trials. 2015;16(1):432.","journal-title":"Trials."},{"key":"4711_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jclinepi.2018.04.011","volume":"100","author":"L Jefferson","year":"2018","unstructured":"Jefferson L, Fairhurst C, Brealey S, Coleman E, Cook L, Hewitt C, et al. Remote or on-site visits were feasible for the initial setup meetings with hospitals in a multicenter surgical trial: an embedded randomized trial. J Clin Epidemiol. 2018;100:13\u201321.","journal-title":"J Clin Epidemiol"},{"key":"4711_CR23","unstructured":"Nuffield Department of Population Health University of Oxford. How to set up a trial in nine days. https:\/\/www.ndph.ox.ac.uk\/longer-reads\/how-to-set-up-a-trial-in-nine-days [Accessed 4 Jun 2020]."},{"issue":"6924","key":"4711_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/bmj.308.6924.283","volume":"308","author":"DG Altman","year":"1994","unstructured":"Altman DG. The scandal of poor medical research. BMJ. 1994;308(6924):283\u20134.","journal-title":"BMJ."},{"issue":"1","key":"4711_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/CVM-1-1-003","volume":"1","author":"I Chalmers","year":"2000","unstructured":"Chalmers I. Current controlled trials: an opportunity to help improve the quality of clinical research. Trials. 2000;1(1):3.","journal-title":"Trials."},{"key":"4711_CR26","unstructured":"Good Clinical Trials Collaborative 2020 https:\/\/wellcome.ac.uk\/what-we-do\/our-work\/good-clinical-trials-collaborative [Accessed 16 Jun 2020]."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-020-04711-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04711-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T00:15:19Z","timestamp":1631319319000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04711-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4711"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04711-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EJM is the Chair of the UK Trial Managers\u2019 Network Executive Group. The authors declare no other competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"784"}}